These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 37832567)
1. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos RD Lancet HIV; 2023 Nov; 10(11):e733-e741. PubMed ID: 37832567 [TBL] [Abstract][Full Text] [Related]
2. sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies. Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos R medRxiv; 2023 Apr; ():. PubMed ID: 37066200 [TBL] [Abstract][Full Text] [Related]
3. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review. Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764 [TBL] [Abstract][Full Text] [Related]
5. HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST). Egger M; Sauermann M; Loosli T; Hossmann S; Riedo S; Beerenwinkel N; Jaquet A; Minga A; Ross J; Giandhari J; Kouyos RD; Lessells R BMJ Open; 2024 Aug; 14(8):e085819. PubMed ID: 39174068 [TBL] [Abstract][Full Text] [Related]
6. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance. Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582 [TBL] [Abstract][Full Text] [Related]
7. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1. Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975 [TBL] [Abstract][Full Text] [Related]
8. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe. de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282 [TBL] [Abstract][Full Text] [Related]
9. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017. Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022 [TBL] [Abstract][Full Text] [Related]
10. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364 [TBL] [Abstract][Full Text] [Related]
11. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Greig SL; Deeks ED Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454 [TBL] [Abstract][Full Text] [Related]
12. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort. Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727 [TBL] [Abstract][Full Text] [Related]
13. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. Armenia D; Santoro MM; Charpentier C; Bertoli A; Forbici F; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG; Flandre P J Antimicrob Chemother; 2023 Jun; 78(6):1415-1422. PubMed ID: 37258034 [TBL] [Abstract][Full Text] [Related]
15. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review. Tao K; Rhee SY; Chu C; Avalos A; Ahluwalia AK; Gupta RK; Jordan MR; Shafer RW Viruses; 2023 Sep; 15(9):. PubMed ID: 37766338 [No Abstract] [Full Text] [Related]
16. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D D2EFT Study Group Lancet HIV; 2024 Jul; 11(7):e436-e448. PubMed ID: 38788744 [TBL] [Abstract][Full Text] [Related]
17. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance. Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149 [TBL] [Abstract][Full Text] [Related]
19. A systematic review of the genetic mechanisms of dolutegravir resistance. Rhee SY; Grant PM; Tzou PL; Barrow G; Harrigan PR; Ioannidis JPA; Shafer RW J Antimicrob Chemother; 2019 Nov; 74(11):3135-3149. PubMed ID: 31280314 [TBL] [Abstract][Full Text] [Related]
20. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]